Fear of new or recurrent melanoma after treatment for localised melanoma

Katy J L Bell, Yachna Mehta, Robin M Turner, Rachael L Morton, Mbathio Dieng, Robyn Saw, Pascale Guitera, Kirsten McCaffery, Donald Low, Cynthia Low, Marisa Jenkins, Les Irwig, Angela C Webster

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)

Abstract

OBJECTIVE: To estimate the amount of fear of new or recurrent melanoma among people treated for localised melanoma in an Australian specialist centre.

METHODS: We randomly selected 400 potential participants from all those treated for localised melanoma at the Melanoma Institute Australia during 2014 (n = 902). They were asked to complete an adapted version of the Fear of Cancer Recurrence Inventory (FCRI). We calculated summary statistics for demographics, clinical variables and total FCRI and subscale scores.

RESULTS: 215 people (54%) completed the FCRI questionnaire. The overall mean severity subscale score was was 15.0 (95% CI 14.0-16.1). A high proportion of participants had scores above a proposed threshold to screen for clinical fear of cancer recurrence (77% and 63% of participants with and without new or recurrent melanoma had severity subscale scores ≥ 13). Most participants also had scores above a threshold found to have high specificity for clinical fear of cancer recurrence (65% and 48% of participants with and without new or recurrent melanoma had severity subscale scores ≥ 16). The severity subscale appeared to discriminate well between groups with differing levels of risk of new or recurrent melanoma.

CONCLUSIONS: There is a substantial amount of fear of new or recurrent melanoma among this population, despite most having a very good prognosis.

Original languageEnglish
Pages (from-to)1784-1791
Number of pages8
JournalPsycho-Oncology
Volume26
Issue number11
DOIs
Publication statusPublished - 1 Nov 2017

Fingerprint

Fear
Melanoma
Recurrence
Neoplasms
Equipment and Supplies
Demography
Population

Cite this

Bell, K. J. L., Mehta, Y., Turner, R. M., Morton, R. L., Dieng, M., Saw, R., ... Webster, A. C. (2017). Fear of new or recurrent melanoma after treatment for localised melanoma. Psycho-Oncology, 26(11), 1784-1791. https://doi.org/10.1002/pon.4366
Bell, Katy J L ; Mehta, Yachna ; Turner, Robin M ; Morton, Rachael L ; Dieng, Mbathio ; Saw, Robyn ; Guitera, Pascale ; McCaffery, Kirsten ; Low, Donald ; Low, Cynthia ; Jenkins, Marisa ; Irwig, Les ; Webster, Angela C. / Fear of new or recurrent melanoma after treatment for localised melanoma. In: Psycho-Oncology. 2017 ; Vol. 26, No. 11. pp. 1784-1791.
@article{ed416647ca8d48e695771d14e7a6c91e,
title = "Fear of new or recurrent melanoma after treatment for localised melanoma",
abstract = "OBJECTIVE: To estimate the amount of fear of new or recurrent melanoma among people treated for localised melanoma in an Australian specialist centre.METHODS: We randomly selected 400 potential participants from all those treated for localised melanoma at the Melanoma Institute Australia during 2014 (n = 902). They were asked to complete an adapted version of the Fear of Cancer Recurrence Inventory (FCRI). We calculated summary statistics for demographics, clinical variables and total FCRI and subscale scores.RESULTS: 215 people (54{\%}) completed the FCRI questionnaire. The overall mean severity subscale score was was 15.0 (95{\%} CI 14.0-16.1). A high proportion of participants had scores above a proposed threshold to screen for clinical fear of cancer recurrence (77{\%} and 63{\%} of participants with and without new or recurrent melanoma had severity subscale scores ≥ 13). Most participants also had scores above a threshold found to have high specificity for clinical fear of cancer recurrence (65{\%} and 48{\%} of participants with and without new or recurrent melanoma had severity subscale scores ≥ 16). The severity subscale appeared to discriminate well between groups with differing levels of risk of new or recurrent melanoma.CONCLUSIONS: There is a substantial amount of fear of new or recurrent melanoma among this population, despite most having a very good prognosis.",
author = "Bell, {Katy J L} and Yachna Mehta and Turner, {Robin M} and Morton, {Rachael L} and Mbathio Dieng and Robyn Saw and Pascale Guitera and Kirsten McCaffery and Donald Low and Cynthia Low and Marisa Jenkins and Les Irwig and Webster, {Angela C}",
note = "This article is protected by copyright. All rights reserved.",
year = "2017",
month = "11",
day = "1",
doi = "10.1002/pon.4366",
language = "English",
volume = "26",
pages = "1784--1791",
journal = "Psycho-Oncology",
issn = "1057-9249",
publisher = "Wiley Blackwell (American Society Bone & Mineral Research)",
number = "11",

}

Bell, KJL, Mehta, Y, Turner, RM, Morton, RL, Dieng, M, Saw, R, Guitera, P, McCaffery, K, Low, D, Low, C, Jenkins, M, Irwig, L & Webster, AC 2017, 'Fear of new or recurrent melanoma after treatment for localised melanoma' Psycho-Oncology, vol. 26, no. 11, pp. 1784-1791. https://doi.org/10.1002/pon.4366

Fear of new or recurrent melanoma after treatment for localised melanoma. / Bell, Katy J L; Mehta, Yachna; Turner, Robin M; Morton, Rachael L; Dieng, Mbathio; Saw, Robyn; Guitera, Pascale; McCaffery, Kirsten; Low, Donald; Low, Cynthia; Jenkins, Marisa; Irwig, Les; Webster, Angela C.

In: Psycho-Oncology, Vol. 26, No. 11, 01.11.2017, p. 1784-1791.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Fear of new or recurrent melanoma after treatment for localised melanoma

AU - Bell, Katy J L

AU - Mehta, Yachna

AU - Turner, Robin M

AU - Morton, Rachael L

AU - Dieng, Mbathio

AU - Saw, Robyn

AU - Guitera, Pascale

AU - McCaffery, Kirsten

AU - Low, Donald

AU - Low, Cynthia

AU - Jenkins, Marisa

AU - Irwig, Les

AU - Webster, Angela C

N1 - This article is protected by copyright. All rights reserved.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - OBJECTIVE: To estimate the amount of fear of new or recurrent melanoma among people treated for localised melanoma in an Australian specialist centre.METHODS: We randomly selected 400 potential participants from all those treated for localised melanoma at the Melanoma Institute Australia during 2014 (n = 902). They were asked to complete an adapted version of the Fear of Cancer Recurrence Inventory (FCRI). We calculated summary statistics for demographics, clinical variables and total FCRI and subscale scores.RESULTS: 215 people (54%) completed the FCRI questionnaire. The overall mean severity subscale score was was 15.0 (95% CI 14.0-16.1). A high proportion of participants had scores above a proposed threshold to screen for clinical fear of cancer recurrence (77% and 63% of participants with and without new or recurrent melanoma had severity subscale scores ≥ 13). Most participants also had scores above a threshold found to have high specificity for clinical fear of cancer recurrence (65% and 48% of participants with and without new or recurrent melanoma had severity subscale scores ≥ 16). The severity subscale appeared to discriminate well between groups with differing levels of risk of new or recurrent melanoma.CONCLUSIONS: There is a substantial amount of fear of new or recurrent melanoma among this population, despite most having a very good prognosis.

AB - OBJECTIVE: To estimate the amount of fear of new or recurrent melanoma among people treated for localised melanoma in an Australian specialist centre.METHODS: We randomly selected 400 potential participants from all those treated for localised melanoma at the Melanoma Institute Australia during 2014 (n = 902). They were asked to complete an adapted version of the Fear of Cancer Recurrence Inventory (FCRI). We calculated summary statistics for demographics, clinical variables and total FCRI and subscale scores.RESULTS: 215 people (54%) completed the FCRI questionnaire. The overall mean severity subscale score was was 15.0 (95% CI 14.0-16.1). A high proportion of participants had scores above a proposed threshold to screen for clinical fear of cancer recurrence (77% and 63% of participants with and without new or recurrent melanoma had severity subscale scores ≥ 13). Most participants also had scores above a threshold found to have high specificity for clinical fear of cancer recurrence (65% and 48% of participants with and without new or recurrent melanoma had severity subscale scores ≥ 16). The severity subscale appeared to discriminate well between groups with differing levels of risk of new or recurrent melanoma.CONCLUSIONS: There is a substantial amount of fear of new or recurrent melanoma among this population, despite most having a very good prognosis.

UR - http://www.scopus.com/inward/record.url?scp=85011659715&partnerID=8YFLogxK

U2 - 10.1002/pon.4366

DO - 10.1002/pon.4366

M3 - Article

VL - 26

SP - 1784

EP - 1791

JO - Psycho-Oncology

JF - Psycho-Oncology

SN - 1057-9249

IS - 11

ER -

Bell KJL, Mehta Y, Turner RM, Morton RL, Dieng M, Saw R et al. Fear of new or recurrent melanoma after treatment for localised melanoma. Psycho-Oncology. 2017 Nov 1;26(11):1784-1791. https://doi.org/10.1002/pon.4366